Head to head

Cagrilintide vs Semaglutide

MetabolicGLP-1 / incretin

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Usually stacked — and Semaglutide rests on firmer evidence

Cagrilintide and Semaglutide appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you are picking one, the evidence is the honest tiebreak: Semaglutide has an approved label and the randomized trial package behind it, while Cagrilintide has controlled human trials behind it, without an approval. That is a difference in how much is known, not a verdict on how well either works.

What you are actually choosing between

Before anything else: the dataset lists Cagrilintide and Semaglutide in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

These sit in different classes. Cagrilintide is a metabolic compound; Semaglutide is a GLP-1 / incretin agonist. They get compared because of where they overlap, not because they are interchangeable.

The overlap is appetite control, fat loss, and metabolic health. On this site's goal weighting — an editorial priority score, not a measure of effect size — Cagrilintide rates 5/5 for appetite control and Semaglutide rates 4/5.

The evidence

This is the part that decides most of it. Semaglutide has an approved label and the randomized trial package behind it. Cagrilintide has controlled human trials behind it, without an approval — investigational; standalone long-term data does not exist yet. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

Cagrilintide is a subcutaneous injection; Semaglutide is a subcutaneous injection and taken by mouth. That is the difference most people actually feel: Cagrilintide means reconstituting a vial and injecting; Semaglutide does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Half-lives are close — 7.5 days for Cagrilintide, 7 days for Semaglutide — and both are dosed once a week, so the rhythm of actually running them is the same.

Risk and difficulty

The contraindication lists are not the same: Cagrilintide flags under 18, which Semaglutide does not; Semaglutide flags MTC or MEN2 history, pancreatitis history, and thyroid disease, which Cagrilintide does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Semaglutide is rated intermediate here and Cagrilintide advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

Cagrilintide

Long-acting amylin analogue, not a GLP-1. Phase 2 randomized human trials dosed 0.3 to 4.5 mg once weekly with 4-week step-ups, and it is in phase 3 combined with semaglutide as CagriSema. It is investigational and NOT approved anywhere as a standalone product. Amylin analogues act on satiety through a different receptor to GLP-1, which is the rationale for the combination, but standalone long-term data does not yet exist.

Semaglutide

GLP-1 receptor agonist with large randomized human trials behind it and FDA approval for type 2 diabetes and weight management under brand names.

Side by side

The numbers

Cagrilintide compared with Semaglutide
Attribute	Cagrilintide	Semaglutide
Class	Metabolic	GLP-1 / incretin
Routes	Subcutaneous	Subcutaneous, Oral
Dose range	300 mcg–4.5 mg (typical 2.4 mg)	250 mcg–2.4 mg (typical 1 mg)
Frequency	Once a week	Once a week
Half-life	7.5 days	7 days
Cycle length	No fixed cycle	No fixed cycle
Experience	Advanced	Intermediate
Evidence	Controlled human trials	Approved (FDA/EMA)
Contraindications	Pregnant / nursing Under 18	Pregnant / nursing MTC or MEN2 history Pancreatitis history Thyroid disease
Side effects	Nausea, generally milder than with a GLP-1 at equivalent appetite suppression Constipation Injection site reactions Reduced appetite and early satiety	Nausea, especially in the days after a dose increase Constipation or diarrhoea Reduced appetite and early satiety Fatigue during titration

Turn a typical dose into a mark on the syringe: CagrilintideSemaglutide

Goals

Where they overlap, and where they do not

Goal	Cagrilintide	Semaglutide
appetite control	Cagrilintide: 5/5	Semaglutide: 4/5
fat loss	Cagrilintide: 4/5	Semaglutide: 4/5
metabolic health	Cagrilintide: 3/5	Semaglutide: 4/5
inflammationone only	Cagrilintide: —	Semaglutide: 2/5

They overlap on 3 goals and diverge on 1. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCagrilintideMechanism, protocol, storage, sources.MonographSemaglutideMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.